



NEWS RELEASE

# CRINETICS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

2023-11-21

SAN DIEGO – November 21, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City.

Details of the fireside chat are as follows:

6th Annual Evercore ISI HealthCONx Conference:

Date: Tuesday, November 28, 2023

Time: 3:50 p.m. Eastern Time

Piper Sandler 35th Annual Healthcare Conference:

Date: Thursday, November 30, 2023

Time: 8:00 a.m. Eastern Time

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics' website on **our events page**.

If you are interested in arranging a 1×1 meeting with management, please contact your Cantor representative.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. **Paltusotine**, an

investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for **CRN04894** a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the Company's **drug candidates** are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

---

Contact:

Chas Schultz

VP, IR & Corporate Communications

**cschultz@crinetics.com**

**(858) 450-6464**

Investors / Media:

Corey Davis

LifeSci Advisors

**cdavis@lifesciadvisors.com**

**(212) 915-2577**

Jenn Gordon

Spectrum Science

**jgordon@spectrumscience.com**

**(202) 957-7795**

Source: Crinetics Pharmaceuticals, Inc.